Non-Ulcer Dyspepsia and Gastric Cytology

Pathobiology ◽  
1958 ◽  
Vol 21 (2) ◽  
pp. 608-613
Author(s):  
R.O.K. Schade
Keyword(s):  
Non Ulcer Dyspepsia ◽  
Gastric Cytology

An Efficient and Improved Process for the Synthesis of Itopride Hydrochloride and Trimethobenzamide Hydrochloride

2018 ◽  
Vol 15 (4) ◽  
pp. 572-575 ◽  
Author(s):  
Ponnusamy Kannan ◽  
Samuel I.D. Presley ◽  
Pallikondaperumal Shanmugasundaram ◽  
Nagapillai Prakash ◽  
Deivanayagam Easwaramoorthy
Keyword(s):  
Large Scale ◽  
Hydroxylamine Hydrochloride ◽  
Scale Production ◽  
One Pot ◽  
Hydrochloride Salt ◽  
Environmental Friendly ◽  
Large Scale Production ◽  
Non Ulcer Dyspepsia ◽  
Itopride Hydrochloride ◽  
Yield And Purity

Aim and Objective: Itopride is a prokinetic agent used for treating conditions like non-ulcer dyspepsia. Itopride is administered as its hydrochloride salt. Trimethobenzamide is used for treating nausea and vomiting and administered as its hydrochloride salt. The aim is to develop a novel and environmental friendly method for large-scale production of itopride and trimethobenzamide. Materials and Methods: Itopride and trimethobenzamide can be prepared from a common intermediate 4- (dimethylaminoethoxy) benzyl amine. The intermediate is prepared from one pot synthesis using Phyrdroxybenzaldehye and zinc dust and further reaction of the intermediate with substituted methoxy benzoic acid along with boric acid and PEG gives itopride and trimethobenzamide. Results: The intermediate 4-(dimethylaminoethoxy) benzylamine is prepared by treating p-hydroxybenzaldehyde and 2-dimethylaminoethyl chloride. The aldehyde formed is treated with hydroxylamine hydrochloride. The intermediate is confirmed by NMR and the purity is analysed by HPLC. Conclusion: Both itopride and trimethobenzamide were successfully synthesized by this method. The developed method is environmental friendly, economical for large-scale production with good yield and purity.

Analysis of babA, cagE and cagA Genes in Helicobacter pylori from Upper Gastric Patients in the North of Iran

2019 ◽  
Vol 19 (3) ◽  
pp. 274-278 ◽  
Author(s):  
Saba Fakhrieh Asl ◽  
Mehrnaz Pourvahedi ◽  
Ali Mojtahedi ◽  
Mohammad Shenagari
Keyword(s):  
Helicobacter Pylori ◽  
Gastric Diseases ◽  
Specific Primers ◽  
The North ◽  
Different Types ◽  
North Of Iran ◽  
Gastric Biopsies ◽  
Pcr Method ◽  
Non Ulcer Dyspepsia ◽  
H Pylori

Objective:Helicobacter pylori is a Gram-negative bacterium which has a serious effect on up to half of the world’s population and has been related to different gastric diseases. The goal of this study was to assess the frequency of babA, cagE and cagA genotypes among H. pylori strains isolated from gastric biopsies of endoscopic patients in the north of Iran.Methods:The present study was performed on 90 strains of H. pylori isolated from patients with gastric diseases (Gastric ulcer (GU), Duodenal ulcer (DU), Gastritis (G), Non-ulcer dyspepsia (NUD) and Gastric adenocarcinoma (GC)). DNA was extracted from all isolated strains and PCR method was performed to detect the prevalence of babA2, cagE and cagA genes using specific primers.Results:Among 90 samples of H. pylori, babA2, cagE, and cagA genes were detected in 42.2%, 30% and 82.2% of strains respectively. The statistical analysis showed that the prevalence of cagA gene in GU, G, DU, and NUD was significantly higher than other genes. Moreover, cagA, and babA2 genes were significantly more prevalent in GC patients compared to cagE gene. Our isolates exhibited 8 distinct arrangements of virulence patterns. The occurrence of cagA (35.6%) was the most prevalent pattern followed by cagA/babA2 (20%) and cagA/babA2/cagE (14.4%).Conclusion:In summary, as first report from Guilan province in the north of Iran, we showed significant association between the presence of babA2, cagE, and cagA genes in different types of gastric disorders.

GASTRIC CYTOLOGY

1968 ◽  
Vol 1 (14) ◽  
pp. 588-589 ◽  
Author(s):  
K. L. Withers ◽  
B. J. Way ◽  
S. Miller
Keyword(s):  
Gastric Cytology

scholarly journals Efficacy and safety of Si-Jun-Zi-Tang-based therapies for functional (non-ulcer) dyspepsia: a meta-analysis of randomized controlled trials

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yaping Wang ◽  
Bin Liu ◽  
Xiuqiong Fu ◽  
Tiejun Tong ◽  
Zhiling Yu
Keyword(s):  
Relapse Rate ◽  
Large Scale ◽  
Primary Outcome ◽  
Response Rate ◽  
Meta Analysis ◽  
Risk Of Bias ◽  
Efficacy And Safety ◽  
History Of ◽  
Non Ulcer Dyspepsia

Abstract Background The traditional Chinese medicine formula Si-Jun-Zi-Tang (SJZT) has a long history of application in the treatment of functional dyspepsia (non-ulcer dyspepsia, FD)-like symptoms. SJZT-based therapies have been claimed to be beneficial in managing FD. This study aimed to assess the efficacy and safety of SJZT-based therapies in treating FD by meta-analysis. Methods Systematic searches for RCTs were conducted in seven databases (up to February 2019) without language restrictions. Data were analyzed using Cochrane RevMan software version 5.3.0 and Stata software version 13.1, and reported as relative risk (RR) or odds ratio (OR) with 95% confidence intervals (CIs). The primary outcome was response rate and the secondary outcomes were gastric emptying, quality of life, adverse effects and relapse rate. The quality of evidence was evaluated according to criteria from the Cochrane risk of bias. Results A total of 341 potentially relevant publications were identified, and 12 RCTs were eligible for inclusion. For the response rate, there was a statically significant benefit in favor of SJZT-based therapies (RR = 1.23; 95% CI 1.17 to 1.30). However, the benefit was limited to modified SJZT (MSJZT). The relapse rate of FD patients received SJZT-based therapies was lower than that of patients who received conventional medicines (OR = 0.23; 95% CI 0.10 to 0.51). No SJZT-based therapies-related adverse effect was reported. Conclusion SJZT-based prescriptions may be effective in treating FD and no serious side-effects were identified, but the effect on response rate appeared to be limited to MSJZT. The results should be interpreted with caution as all the included studies were considered at a high risk of bias. Standardized, large-scale and strictly designed RCTs are needed to further validate the benefits of SJZT-based therapies for FD management. Trial registration Systematic review registration: [PROSPERO registration: CRD42019139136].

Cimetidine and non-ulcer dyspepsia

1986 ◽  
Vol 24 (1) ◽  
pp. 3-4
Keyword(s):  
Peptic Ulcer ◽  
Abdominal Pain ◽  
Gastric Acid ◽  
Reflux Oesophagitis ◽  
Data Sheet ◽  
Organic Disease ◽  
Dyspeptic Symptoms ◽  
Proven Efficacy ◽  
Non Ulcer Dyspepsia ◽  
Upper Abdominal

Many patients with dyspepsia do not appear to have organic disease.1 Cimetidine (Tagamet) is of proven efficacy in the treatment of peptic ulcer and reflux oesophagitis, but is widely used for the treatment of dyspepsia without investigation.2, 3 The data sheet for cimetidine now states that the drug is indicated “where reduction of gastric acid by Tagamet has been shown to be beneficial: persistent dyspeptic symptoms with or without ulceration, particularly meal-related upper abdominal pain”. Is this indication valid?

Follow-Up Study of Individuals with Untreated Campylobacter pylori-Associated Gastritis and of Noninfected Persons with Non-Ulcer Dyspepsia

1988 ◽  
Vol 157 (6) ◽  
pp. 1245-1249 ◽  
Author(s):  
W. Langenberg ◽  
E. A. J. Rauws ◽  
H. J. Houthoff ◽  
J. H. Oudbier ◽  
C. G. van Bohemen ◽  
...  
Keyword(s):  
Campylobacter Pylori ◽  
Follow Up Study ◽  
Non Ulcer Dyspepsia
Sign in / Sign up

Export Citation Format

Share Document